Exact Sciences CMS approval expected by early September, says Canaccord Canaccord met with Exact Sciences management and came away confident in the CMS' preliminary reimbursement amount, which the firm expects by early September. Canaccord also noted checks into the company's call center indicated strong interest in Cologuard and it expects targeted digital advertising to raise awareness of its product. The firm raised its price target on the stock to $21 from $20 and keeps its Buy rating on the shares.
Exact Sciences upgraded to Buy from Hold at Lake Street Lake Street Capital Markets analyst Bruce Jackson upgraded Exact Sciences to Buy and raised his price target for shares to $30 from $27. The company's Q2 report showed better than expected gross margins and the stock's risk/reward is appealing, Jackson tells investors.